Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society 1 state that “a little over 1.9

Development 64

Development Research Drugs Antibody 64

Drug Discovery World

DECEMBER 8, 2023

News round-up for 4-8 December by DDW Digital Content Editor Diana Spencer. DNA therapy effective against chemo-resistant ovarian cancer A novel DNA vaccine in combination with chemotherapy has demonstrated promising clinical results against a deadly form of ovarian cancer.

Drugs 52

Drugs DNA Clinical Trials Clinical Trials 52

pharmaphorum

FEBRUARY 24, 2022

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer. At least 41,000 women in the UK are estimated to be living with ovarian cancer.

Regulation 52

Regulation Gene Drugs Marketing 52

Drug Discovery World

JUNE 16, 2023

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas. GSK faces RSV vaccine threat from rival Pfizer An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market.

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

MARCH 3, 2023

News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer. As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day , DDW has also reported on a number of developments in cancer drug discovery this week.

Drugs 52

Drugs Gene Expression Genome Genomics 52

The Pharma Data

DECEMBER 21, 2020

21, 2020 — Oral contraceptives have a lasting protective effect against ovarian and endometrial cancer, according to a study published online Dec. 17 in Cancer Research. Biobank, born between 1939 and 1970, to clarify the time-dependent effects between long-term oral contraceptive use and cancer risk. MONDAY, Dec.

HR 52

HR Biobanking Research Development 52

Drug Discovery World

JULY 14, 2023

News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. awarded to progress ovarian cancer cell therapy NK:IO has been awarded £1.6m ($2.1m) in grant funding from Innovate UK’s New Cancer Therapeutics programme. £1m

Gene Therapy 52

Gene Therapy Life Science Drugs Gene 52

XTalks

NOVEMBER 30, 2023

Pfizer spinout SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has received US Food and Drug Administration (FDA) approval for the treatment of desmoid tumors, an ultra-rare subtype of non-cancerous soft tissue sarcomas that can cause severe pain and disfigurement.

FDA Approval 101

FDA Approval Trials Clinical Trials Clinical Trials 101

The Pharma Data

NOVEMBER 27, 2020

27, 2020 — Freezing their eggs or ovarian tissue before breast cancer treatment increases survivors’ chances of having children after recovery, a new study finds. Treatment often includes chemotherapy, which can damage ovarian tissue, and long-term hormone treatment, which can cause early menopause.

Hormones 52

Hormones Doctors Doctor Research 52

The Pharma Data

JANUARY 27, 2021

27, 2021 — Aspirin use may improve survival for bladder and breast cancer , according to a study published online Jan. years) participating in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (1993 to 2001). However, there was no survival benefit with esophageal, gastric, pancreatic, or uterine cancer.

Trials 52

Trials Development Research 52

pharmaphorum

AUGUST 18, 2021

Jemperli (dostarlimab) can now be used to treat adults with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours – regardless of where they are located in the body – in addition to its earlier approval in dMMR-positive endometrial cancer. billion takeover of Tesaro in 2019.

Drugs 52

Drugs Sales FDA Approval Marketing 52

pharmaphorum

FEBRUARY 22, 2021

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer indication in the US. It’s news that will likely hand market share to Roche and Pfizer/Merck KGaA, whose respective immunotherapies Tecentriq and Bavencio have bladder cancer indications.

Trials 52

Trials Sales Marketing Drugs 52

pharmaphorum

APRIL 23, 2021

billion acquisition of Tesaro, for certain patients with endometrial cancer. . With Jemperli , a PD-1 class drug, GSK is a latecomer to the immunotherapy party with a host of other competitors already on the market in various cancers. The post FDA approves under-pressure GSK’s Jemperli for endometrial cancer appeared first on.

FDA Approval 52

FDA Approval Marketing Drugs Licensing 52

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Gene 52

Gene Hormones DNA Medicine 52

pharmaphorum

OCTOBER 6, 2020

Johnson & Johnson has agreed to pay more than $100 million to settle over 1,000 lawsuits that allege the company’s Baby Powder talc products caused cancer, according to Bloomberg. J&J refutes that assertion, and insists there is no asbestos in its talc, although it has been at odds on the latter issue with the FDA.

Sales 57

Sales Production Trials Development 57

pharmaphorum

MAY 11, 2021

“This is great news for the aHUS community in Scotland, as ravulizumab will reduce the number of infusions needed per year, significantly improving the quality of life for all those living with the condition,” according to David Kavanagh, professor of complement therapeutics at the NRCTC.

Medicine 52

Medicine Sales Drugs Trials 52

XTalks

MAY 31, 2023

CytoMed Therapeutics is a prominent R&D company based in Singapore, specializing in cell-based immunotherapy for the treatment of cancer. These cutting-edge technologies have enabled CytoMed Therapeutics to develop a robust pipeline of cell-based therapies targeting a wide range of cancers. The IPO may generate around $15.0

Clinical Trials 97

Clinical Trials Clinical Trials Trials Production 97

The Pharma Data

MARCH 5, 2021

Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9

Antibody 52

Antibody Trials Development Clinical Development 52

The Pharma Data

NOVEMBER 30, 2020

“It’s troubling to think how many Americans have been using talc-based cosmetics products potentially contaminated with asbestos,” Leiba said in an EWG news release. Thousands of people have filed lawsuits against the company, claiming the product caused cancer, the study said. The analysis was published Nov.

Containment 52

Containment Production Cosmetics Contamination 52

pharmaphorum

NOVEMBER 16, 2022

has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. RxDx Assay – Roche’s immunohistochemistry (IHC) companion diagnostic for identifying ovarian patients eligible for ELAHERE – has been contemporaneously approved by the FDA.

FDA Approval 67

FDA Approval Protein Trials Packaging 67

XTalks

NOVEMBER 16, 2022

has won US Food and Drug Administration (FDA) approval for its antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer. positive ovarian, fallopian tube or primary peritoneal cancers who have received one to three previous lines of systemic therapy.

FDA Approval 98

FDA Approval Antibody Drugs Trials 98

The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme.

HR 52

HR Medicine Hormones Trials 52

Pharma Times

MARCH 7, 2024

Ovarian high-grade serous carcinoma is the most common form of aggressive ovarian cancer

Development 121

Development Research Medicine 121

The Pharma Data

DECEMBER 9, 2020

Below is a roundup of some of this week’s interesting news. The company also announced the successful in vivo validation of the platform in proof-of-concept studies using a cancer xenograft model. The creation of Overland isn’t the only exciting thing happening for international life sciences companies and organizations.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

XTalks

JUNE 16, 2023

The ongoing chemotherapy drug shortage is a critical situation impacting cancer care in the US. The two drugs are often used in combination to treat many types of cancer, including lung, breast and prostate cancers, as well as many leukemias and lymphomas​​. Carlson said, “This is an unacceptable situation.

Drugs 98

Drugs Manufacturing Clinical Supply Chain Clinical Trials 98

Drug Discovery World

APRIL 11, 2024

The Program Committee Chairs commented: “It has been an educational, enlightening, and inspiring week of captivating cancer science and research. Thanks, too, to the members of the AACR for their support of this organisation’s meaningful mission to prevent and cure all cancers. And thanks to the city of San Diego for its hospitality.”

HR 52

HR Antibody In-Vitro DNA 52

The Pharma Data

JUNE 30, 2021

This is promising news for the IBD community.” 1-6 No new safety risks were identified. 1-6 No new safety risks were identified. Lymphoma and other cancers, including skin cancers, can happen in people taking RINVOQ. 1 The exposure-adjusted event rates of adverse events per 100 patient years were 16.0

Medicine 52

Medicine Bacteria Vaccination Vaccine 52

XTalks

AUGUST 3, 2021

The National Council of Negro Women (NCNW) filed a lawsuit last week asking courts to make Johnson & Johnson create equally targeted “corrective marketing,” and/or fund outreach efforts warning Black women and their families about the risk of ovarian cancer associated with its product.

Containment 98

Containment Production Contamination Marketing 98

pharmaphorum

SEPTEMBER 21, 2022

Enter Puma Biotech, which is paying a modest $7 million upfront for rights to alisertib (formerly MLN8237) and plans to run clinical trials of the compound in breast and lung cancers. Aurora kinase A is an enzyme that is involved in cell division and proliferation, and is often overexpressed in cancers.

Drugs 62

Drugs HR Licensing Licensing 62

pharmaphorum

OCTOBER 21, 2021

CAR-T therapies have revolutionised the treatment of some blood cancers, but so far haven’t been able to repeat that success in solid tumours. Its lead candidate it LEU-011, a NKG2D CAR-T therapy in preclinical development for platinum resistant ovarian cancer. When bound, the immune cells trigger cancer cell death.

Engineer 92

Engineer Clinical Trials Clinical Trials Genetics 92

pharmaphorum

JANUARY 27, 2023

A study by UK researchers has found that buying patterns for over-the-counter (OTC) medicines for pain and indigestion, recorded using a store loyalty card, could be used to pick up early symptoms of ovarian cancer. Image credit: Lancaster University The post Could your loyalty card help spot cancer?

Research 52

Research Medicine Scientist 52

Pharma Marketing Network

MARCH 12, 2021

Ovarian cancer is a devastating disease, with the lowest survival rate of gynecologic cancers, striking and killing women of all ages and ethnicities. We sought to reach women to encourage awareness, understanding, and dialogue about the importance of education and early detection in ovarian cancer. So, ‘OvaryAct’.

Branding 93

Branding Marketing Development Research 93

Drug Discovery World

FEBRUARY 20, 2023

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, according to a recent report by analytics company Phesi. AstraZeneca and Meck’s Lynparza (olaparib) was approved in both the EU and the US in 2022 for patients with early-stage breast cancer.

Drug Trials 52

Drug Trials Trials Clinical Trials Clinical Trials 52

pharmaphorum

MARCH 19, 2021

NICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. The post NICE backs ovarian cancer and multiple myeloma combination drugs appeared first on.

Drugs 92

Drugs Clinical Trials Clinical Trials Marketing 92

pharmaphorum

NOVEMBER 14, 2022

GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patients with a specific mutation. That was due last Friday, but cancelled when GSK opted to withdraw the approval. GSK acquired Zejula as part of its $5.1

Sales 52

Sales Drugs Trials Marketing 52

Scienmag

MARCH 18, 2022

Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented at a Seminal Session during the Society for Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer in March 2022.

Trials 69

Trials 69

pharmaphorum

JUNE 6, 2022

Eisai’s first-ever attempt at developing an antibody-drug conjugate for cancer was rewarded with a $3.1 billion licensing deal from Bristol-Myers Squibb, and new data reported at ASCO has given a glimpse into its potential. positive ovarian cancer, the ADC achieved an overall response rate (ORR) of 25% at a dose of 0.9

Antibody 57

Antibody Drugs Licensing Licensing 57